Overview

Efficacy and Safety Study of ABT-436 in Major Depressive Disorder

Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Citalopram
Dexetimide